RecruitingPhase 1 / Phase 2NCT07070232
9
studies recruiting now
as of 7 Sept 2026
37
studies registered in total
as of 7 Sept 2026
28
countries with a recruiting site
as of 7 Sept 2026
8 Aug 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1NCT04902443
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
RecruitingPhase 2NCT05253131
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
RecruitingPhase 1 / Phase 2NCT07111520
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 2 / Phase 3NCT06788990
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 9 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new L1 syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About L1 syndrome
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).